{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T22:09:19Z","timestamp":1794866959277,"version":"4.9.1"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The present study aimed to investigate the incidence of hepatocellular carcinoma (HCC) and factors related to HCC occurrence after direct-acting antiviral (DAA) treatment in the Fukushima Liver Academic Group (FLAG). We conducted a multicenter retrospective cohort study of 1068 patients without cirrhosis (NC) or with compensated liver cirrhosis (LC) who achieved a sustained virologic response (SVR). First, we compared the cumulative HCC incidence and survival rates in NC (n = 880) and LC (n = 188) patients without a history of HCC treatment. Second, we performed multivariate analysis of factors related to HCC occurrence after DAA treatment. Overall, the average age was 65 years, and the male\/female ratio was 511\/557. Thirty-nine (4%) patients developed HCC. The cumulative 4-year HCC incidence and survival rates were 3.0% and 99.8% in NC patients and 11.5% and 98.5% in LC patients, respectively. The independent factors affecting HCC occurrence identified by multivariate analysis were the serum albumin (ALB) level before SVR for NC patients and the ALBI score, platelet count, and diabetes before SVR for LC patients. The factors related to HCC occurrence differed between NC and LC patients. Careful surveillance of post-SVR patients with these risk factors is needed.<\/jats:p>","DOI":"10.1371\/journal.pone.0243473","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T20:52:21Z","timestamp":1607374341000},"page":"e0243473","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":36,"title":["Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5359-9465","authenticated-orcid":true,"given":"Kazumichi","family":"Abe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoe","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Kogure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"key":"pone.0243473.ref001","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"RL Morgan","year":"2013","journal-title":"Ann Intern Med"},{"key":"pone.0243473.ref002","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cgh.2009.10.026","article-title":"Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis","volume":"8","author":"AK Singal","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"pone.0243473.ref003","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"F Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"pone.0243473.ref004","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/apt.14593","article-title":"Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study","volume":"47","author":"AW Singer","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0243473.ref005","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"5","author":"GN Ioannou","year":"2017","journal-title":"J Hepatol"},{"key":"pone.0243473.ref006","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2018.07.024","article-title":"Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C","volume":"69","author":"GN Ioannou","year":"2018","journal-title":"J Hepatol"},{"key":"pone.0243473.ref007","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.26442","article-title":"alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C","volume":"58","author":"Y Asahina","year":"2013","journal-title":"Hepatology"},{"key":"pone.0243473.ref008","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00535-004-1519-2","article-title":"Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon","volume":"40","author":"M Ikeda","year":"2005","journal-title":"J Gastroenterol"},{"key":"pone.0243473.ref009","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1440-1746.2005.03800.x","article-title":"Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy","volume":"20","author":"H Tokita","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"pone.0243473.ref010","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.3748\/wjg.v13.i39.5180","article-title":"Hepatic steatosis as a possible risk factor for the development of hepatocellular carci- noma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C","volume":"13","author":"A Tanaka","year":"2007","journal-title":"World J Gastroenterol"},{"key":"pone.0243473.ref011","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/hepr.13278","article-title":"Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection","volume":"49","author":"T Watanabe","year":"2019","journal-title":"Hepatol Res"},{"key":"pone.0243473.ref012","first-page":"2205","article-title":"Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study","volume":"19","author":"J Tani","year":"2020","journal-title":"Oncol Lett"},{"key":"pone.0243473.ref013","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores","volume":"157","author":"GN Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"pone.0243473.ref014","doi-asserted-by":"crossref","first-page":"e4157","DOI":"10.1097\/MD.0000000000004157","article-title":"Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy","volume":"95","author":"CF Huang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"pone.0243473.ref015","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/ijc.25585","article-title":"Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy","volume":"128","author":"CH Hung","year":"2011","journal-title":"Int J Cancer"},{"key":"pone.0243473.ref016","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/apt.15597","article-title":"Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis","volume":"51","author":"F Ebel","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0243473.ref017","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence- based approach-the ALBI grade","volume":"33","author":"PJ Johnson","year":"2015","journal-title":"J. Clin. Oncol"},{"key":"pone.0243473.ref018","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/bjc.2016.33","article-title":"Long-term Impact of Liver Function on Curative Therapy for Hepatocellular Carcinoma: Application of the ALBI Grade","volume":"114","author":"H Toyoda","year":"2016","journal-title":"Br J Cancer"},{"key":"pone.0243473.ref019","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000452846","article-title":"Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan society of hepatology: A comparison with the liver damage and child-pugh classifications","volume":"6","author":"A Hiraoka","year":"2017","journal-title":"Liver Cancer"},{"key":"pone.0243473.ref020","first-page":"3074","article-title":"Value of the albumin-bilirubin score in the evaluation of hepatitis B virus-related acute-on-chronic liver failure, liver cirrhosis, and hepatocellular carcinoma","volume":"15","author":"Q Lei","year":"2018","journal-title":"Exp Ther Med"},{"key":"pone.0243473.ref021","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5152\/tjg.2016.15502","article-title":"Albumin-bilirubin score for predicting the in-hospital mortality of acute upper gastrointestinal bleeding in liver cirrhosis: A retrospective study","volume":"27","author":"D Zou","year":"2016","journal-title":"Turk J Gastroenterol"},{"key":"pone.0243473.ref022","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.dld.2018.09.016","article-title":"Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals","volume":"51","author":"member of the Bologna DAA group","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"Suppl 1","key":"pone.0243473.ref023","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2036.2007.03512.x","article-title":"Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease","volume":"26","author":"BB Weksler","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0243473.ref024","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00000441-200309000-00001","article-title":"Predictors and implications of severe hypersplenism in patients with cirrhosis","volume":"326","author":"S Liangpunsakul","year":"2003","journal-title":"Am J Med Sci"},{"key":"pone.0243473.ref025","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000470910","article-title":"Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Genotype 1-Related Chronic Liver Disease","volume":"93","author":"F Ogata","year":"2017","journal-title":"Oncology"},{"key":"pone.0243473.ref026","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/apt.15296","article-title":"The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis","volume":"50","author":"AJ Mecci","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0243473.ref027","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/hep.26087","article-title":"Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C","volume":"57","author":"Y Arase","year":"2013","journal-title":"Hepatology"},{"key":"pone.0243473.ref028","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciw362","article-title":"Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C","volume":"63","author":"M Hedenstierna","year":"2016","journal-title":"Clin Infect Dis"},{"key":"pone.0243473.ref029","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/hepr.13388","article-title":"Hypozincemia Is Associated With Human Hepatocarcinogenesis in Hepatitis C Virus-Related Liver Cirrhosis","volume":"49","author":"R Shigefuku","year":"2019","journal-title":"Hepatol Res"},{"key":"pone.0243473.ref030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00535-018-1495-6","article-title":"Safety and Efficacy of Elbasvir and Grazoprevir in Japanese Hemodialysis Patients With Genotype 1b Hepatitis C Virus Infection","volume":"54","author":"G Suda","year":"2019","journal-title":"J Gastroenterol"},{"key":"pone.0243473.ref031","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/hep.27705","article-title":"Randomized Trial of Interferon- And Ribavirin-Free Ombitasvir\/Paritaprevir\/Ritonavir in Treatment-Experienced Hepatitis C Virus-Infected Patients","volume":"61","author":"K Chayama","year":"2015","journal-title":"Hepatology"},{"key":"pone.0243473.ref032","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00535-019-01556-y","article-title":"Safety and Efficacy of Glecaprevir and Pibrentasvir in Japanese Hemodialysis Patients With Genotype 2 Hepatitis C Virus Infection","volume":"54","author":"G Suda","year":"2019","journal-title":"J Gastroenterol"},{"key":"pone.0243473.ref033","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.27366","article-title":"Concordance of Sustained Virological Response 4, 12, and 24 Weeks Post-Treatment With Sofosbuvir-Containing Regimens for Hepatitis C Virus","volume":"61","author":"EM Yoshida","year":"2015","journal-title":"Hepatology"},{"key":"pone.0243473.ref034","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3350\/cmh.2016.0087","article-title":"Efficacy and Safety of Sofosbuvir-Based Regimens for Treatment in Chronic Hepatitis C Genotype 1 Patients With Moderately Impaired Renal Function","volume":"23","author":"HP Shin","year":"2017","journal-title":"Clin Mol Hepatol"},{"key":"pone.0243473.ref035","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.2040-1124.2010.00074.x","article-title":"Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus","volume":"19","author":"Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus","year":"2010","journal-title":"J Diabetes Investig"},{"key":"pone.0243473.ref036","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: An Inexpensive and Accurate Marker of Fibrosis in HCV Infection. Comparison With Liver Biopsy and Fibrotest","volume":"46","author":"A Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"pone.0243473.ref037","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s12072-019-09988-7","article-title":"APASL HCV Guidelines of Virus-Eradicated Patients by DAA on How to Monitor HCC Occurrence and HBV Reactivation","volume":"13","author":"T Kanda","year":"2019","journal-title":"Hepatol Int"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T17:41:01Z","timestamp":1724002861000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243473"}},"subtitle":[],"editor":[{"given":"Ming-Lung","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,7]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0243473","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.g001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.g002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.g003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.t001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.t002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.t003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.t004","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.t005","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.s002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.s003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.s004","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.s005","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.s006","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.s007","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.s008","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.s009","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.s010","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.s011","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.s012","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.r001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.r002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.r003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0243473.r004","asserted-by":"subject"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,7]]}}}